A drug and ATP binding site in type 1 ryanodine receptor
- PMID: 35580609
- DOI: 10.1016/j.str.2022.04.010
A drug and ATP binding site in type 1 ryanodine receptor
Abstract
The ryanodine receptor (RyR)/calcium release channel on the sarcoplasmic reticulum (SR) is required for excitation-contraction coupling in skeletal and cardiac muscle. Inherited mutations and stress-induced post-translational modifications result in an SR Ca2+ leak that causes skeletal myopathies, heart failure, and exercise-induced sudden death. A class of therapeutics known as Rycals prevent the RyR-mediated leak, are effective in preventing disease progression and restoring function in animal models, and are in clinical trials for patients with muscle and heart disorders. Using cryogenic-electron microscopy, we present a model of RyR1 with a 2.45-Å resolution before local refinement, revealing a binding site in the RY1&2 domain (3.10 Å local resolution), where the Rycal ARM210 binds cooperatively with ATP and stabilizes the closed state of RyR1.
Keywords: Rycals; calcium channels; calmodulin; calstabin; cryoEM; electrophysiology; ion channels; muscular dystrophy; ryanodine receptor; sarcoplasmic reticulum.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of interests A.R.M. serves on the scientific advisory board and the board of directors and is an equity owner of ARMGO. Columbia University also owns equity in ARMGO.
Comment in
-
It takes two to tango: Rycals and ATP snuggle up to bind ryanodine receptors.Structure. 2022 Jul 7;30(7):919-921. doi: 10.1016/j.str.2022.05.022. Structure. 2022. PMID: 35803239
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Research Materials
Miscellaneous